| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3288 |
| Trial ID | NCT05665725 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Siltuximab |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | Timothy Voorhees |
| Other ID(s) | OSU-22031|NCI-2022-10248 |
| Cohort 1 | |||||||
|
|||||||